Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma

Gene Therapy volume 19, pages 967–977 (2012)Cite this article

Subjects

Abstract

S100A2, a member of the S100 family of calcium-binding proteins, has been implicated in carcinogenesis as both a tumor suppressor and stimulator. Here, we characterized promoter activity of S100A2, generated an S100A2 promoter-driven conditionally replicative adenovirus (Ad/SA), and evaluated its anti-tumor activity in vitro and in vivo. Promoter activity of S100A2 was greatly restricted to tumor cells, and the S100A2 promoter bound with typical nuclear targets of epidermal growth factor receptor (EGFR) signaling. EGF-stimulated EGFR phosphorylation induced S100A2 expression and further activated E1A expression of Ad/SA, which was restored by EGFR signal inhibition in a concentration-dependent manner in non-small-cell lung carcinoma (NSCLC). In two EGFR-activated tumor xenograft animal models, Ad/SA exhibited potent anti-tumor activity, whereas cetuximab, an EGFR-targeting anticancer drug, was active transiently or ineffective. Combined treatment with cetuximab or cisplatin plus Ad/SA resulted in enhanced anti-tumor activity. Immunohistochemical analysis of tumor sections showed moderate-to-high grade signals for EGFR and adenovirus, and a reduction in viable cells in Ad/SA-treated tumors. Collectively, these results demonstrate that the S100A2 promoter-driven adenovirus is a potent inhibitor of cancers, and further suggest that S100A2 is a target gene of EGFR signaling pathway in NSCLC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Ko D, Hawkins L, Yu DC . Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 2005; 24: 7763–7774.

    Article  CAS  Google Scholar 

  2. Parato KA, Senger D, Forsyth PA, Bell JC . Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965–976.

    Article  CAS  Google Scholar 

  3. Toth K, Dhar D, Wold WS . Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin Biol Ther 2010; 10: 353–368.

    Article  CAS  Google Scholar 

  4. Liu TC, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N, Kirn D . An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther 2004; 9: 786–803.

    Article  CAS  Google Scholar 

  5. Wolf S, Haase-Kohn C, Pietzsch J . S100A2 in cancerogenesis: a friend or a foe? Amino Acids 2010, E-pub ahead of print; doi:10.1007/s00726-010-0623-2.

  6. Biankin AV, Kench JG, Colvin EK, Segara D, Scarlett CJ, Nguyen NQ et al. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009; 137: 558–568.

    Article  Google Scholar 

  7. Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M et al. S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res 2009; 15: 22–29.

    Article  CAS  Google Scholar 

  8. Lauriola L, Michetti F, Maggiano N, Galli J, Cadoni G, Schäfer BW et al. Prognostic significance of the Ca2+ binding protein S100A2 in laryngeal squamous-cell carcinoma. Int J Cancer 2000; 89: 345–349.

    Article  CAS  Google Scholar 

  9. Ohuchida K, Mizumoto K, Miyasaka Y, Yu J, Cui L, Yamaguchi H et al. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. J Pathol 2007; 213: 275–282.

    Article  CAS  Google Scholar 

  10. Suzuki F, Oridate N, Homma A, Nakamaru Y, Nagahashi T, Yagi K et al. S100A2 expression as a predictive marker for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral cavity. Oncol Rep 2005; 14: 1493–1498.

    CAS  PubMed  Google Scholar 

  11. Wang H, Zhang Z, Li R, Ang KK, Zhang H, Caraway NP et al. Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer. Int J Cancer 2005; 116: 285–290.

    Article  CAS  Google Scholar 

  12. Kirschner RD, Sänger K, Müller GA, Engeland K . Transcriptional activation of the tumor suppressor and differentiation gene S100A2 by a novel p63-binding site. Nucleic Acids Res 2008; 36: 2969–2980.

    Article  CAS  Google Scholar 

  13. van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR . Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem 2009; 284: 13804–13811.

    Article  CAS  Google Scholar 

  14. van Dieck J, Brandt T, Teufel DP, Veprintsev DB, Joerger AC, Fersht AR . Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73. Oncogene 2010; 29: 2024–2035.

    Article  CAS  Google Scholar 

  15. Stoll SW, Zhao X, Elder JT . EGF stimulates transcription of CaN19 (S100A2) in HaCaT keratinocytes. J Invest Dermatol 1998; 111: 1092–1097.

    Article  CAS  Google Scholar 

  16. Xia L, Stoll SW, Liebert M, Ethier SP, Carey T, Esclamado R et al. CaN19 expression in benign and malignant hyperplasias of the skin and oral mucosa: evidence for a role in regenerative differentiation. Cancer Res 1997; 57: 3055–3062.

    CAS  PubMed  Google Scholar 

  17. Deshpande R, Woods TL, Fu J, Zhang T, Stoll SW, Elder JT . Biochemical characterization of S100A2 in human keratinocytes: subcellular localization, dimerization, and oxidative cross-linking. J Invest Dermatol 2000; 115: 477–485.

    Article  CAS  Google Scholar 

  18. Kim J, Cho JY, Kim JH, Jung KC, Yun CO . Evaluation of E1B gene attenuated adenoviruses for cancer gene therapy. Cancer Gene Ther 2002; 9: 725–736.

    Article  CAS  Google Scholar 

  19. Kim J, Kim JH, Choi KJ, Kim PH, Yun CO . E1A- and E1B-double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther 2007; 18: 773–786.

    Article  CAS  Google Scholar 

  20. Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR et al. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res 2010; 16: 541–553.

    Article  CAS  Google Scholar 

  21. Song X, Zhou Y, Jia R, Xu X, Wang H, Hu J et al. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101. Invest Ophthalmol Vis Sci 2010; 51: 2626–2635.

    Article  Google Scholar 

  22. Fan Z, Baselga J, Masui H, Mendelsohn J . Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637–4642.

    CAS  PubMed  Google Scholar 

  23. Reuter CW, Morgan MA, Eckardt A . Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007; 96: 408–416.

    Article  CAS  Google Scholar 

  24. Feng G, Xu X, Youssef EM, Lotan R . Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Res 2001; 61: 7999–8004.

    CAS  PubMed  Google Scholar 

  25. Zhang X, Hunt JL, Shin DM, Chen ZG . Down-regulation of S100A2 in lymph node metastases of head and neck cancer. Head Neck 2007; 29: 236–243.

    Article  Google Scholar 

  26. Lee SW, Tomasetto C, Sager R . Positive selection of candidate tumor-suppressor genes by subtractive hybridization. Proc Natl Acad Sci USA 1991; 88: 2825–2829.

    Article  CAS  Google Scholar 

  27. El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002; 62: 6823–6826.

    CAS  PubMed  Google Scholar 

  28. Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002; 21: 7749–7763.

    Article  CAS  Google Scholar 

  29. Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE, Simm A . S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer 2007; 43: 1935–1943.

    Article  CAS  Google Scholar 

  30. Shimada A, Kano J, Ishiyama T, Okubo C, Iijima T, Morishita Y et al. Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development. Cancer Sci 2005; 96: 668–675.

    Article  CAS  Google Scholar 

  31. Smith SL, Gugger M, Hoban P, Ratschiller D, Watson SG, Field JK et al. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. Br J Cancer 2004; 91: 1515–1524.

    Article  CAS  Google Scholar 

  32. Wicki R, Franz C, Scholl FA, Heizmann CW, Schäfer BW . Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium 1997; 22: 243–254.

    Article  CAS  Google Scholar 

  33. Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brünner N et al. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008; 110: 317–326.

    Article  CAS  Google Scholar 

  34. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10: 8472–8478.

    Article  Google Scholar 

  35. Matsubara D, Niki T, Ishikawa S, Goto A, Ohara E, Yokomizo T et al. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci 2005; 96: 844–857.

    Article  CAS  Google Scholar 

  36. Rehman I, Cross SS, Catto JW, Leiblich A, Mukherjee A, Azzouzi AR et al. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. Prostate 2005; 65: 322–330.

    Article  CAS  Google Scholar 

  37. Vardimon L, Neumann R, Kuhlmann I, Sutter D, Doerfler W . DNA methylation and viral gene expression in adenovirus-transformed and -infected cells. Nucleic Acids Res 1980; 8: 2461–2473.

    Article  CAS  Google Scholar 

  38. Shrestha P, Muramatsu Y, Kudeken W, Mori M, Takai Y, Ilg EC et al. Localization of Ca2+-binding S100 proteins in epithelial tumours of the skin. Virchows Arch 1998; 432: 53–59.

    Article  CAS  Google Scholar 

  39. Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I . Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 2010; 464: 783–788.

    Article  CAS  Google Scholar 

  40. Macdonald JL, Pike LJ . Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system. Proc Nat Acad Sci USA 2008; 105: 112–117.

    Article  CAS  Google Scholar 

  41. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009; 373: 1525–1531.

    Article  CAS  Google Scholar 

  42. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28: 911–917.

    Article  CAS  Google Scholar 

  43. Morgensztern D, Govindan R . Is there a role for cetuximab in non-small cell lung cancer? Clin Cancer Res 2007; 13: 4602s–4605s.

    Article  CAS  Google Scholar 

  44. Kruser TJ, Wheeler DL . Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010; 316: 1083–1100.

    Article  CAS  Google Scholar 

  45. Lee K, Yun ST, Kim YG, Yun Y, Jo EC . Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice. Hepatology 2006; 43: 1063–1073.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by a grant from the Korean Ministry of Knowledge Economy (Grant Number: 00008099). The authors thank Ji-Hyun Lee and Hak-Kyu Joo for their skillful technical assistance in the animal studies, and Sun Yeou Kim (Kyung Hee University) for her kind gift of HaCaT cells.

Author information

Authors and Affiliations

  1. Gene Therapy Laboratory, MOGAM Biotechnology Research Institute, Yongin, Republic of Korea

    K Lee, S-T Yun & E-C Jo

  2. School of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea

    K Lee & B-Y Ahn

  3. Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Republic of Korea

    C-O Yun

Authors
  1. K Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S-T Yun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C-O Yun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B-Y Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E-C Jo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E-C Jo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Gene Therapy website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, K., Yun, ST., Yun, CO. et al. S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma. Gene Ther 19, 967–977 (2012). https://doi.org/10.1038/gt.2011.168

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2011.168

Keywords

Search

Advanced search

Quick links